research centers


Search results: Found 23

Listing 1 - 10 of 23 << page
of 3
>>
Sort by

Article
Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
تأثير ال atorvastatin والثوم على مرضى فرط شحميات الدم

Authors: Zuhair M. Hussien زهير معروف حسين --- Luma T. Ahmed لمى طه أحمد --- Qutuba Gh. Hussain قتيبة غانم حسين
Journal: Diyala Journal of Medicine مجلة ديالى الطبية ISSN: 97642219 Year: 2013 Volume: 5 Issue: 1 Pages: 63-68
Publisher: Diyala University جامعة ديالى

Loading...
Loading...
Abstract

Background: Hyperlipidemia is one of the most common diseases among Iraqi community, and using herbal medicine in treating hyperlipidemia was a good choice to reduce the side effect of recommended drugs with good results of healing, Garlic (Allium sativum) has been used in herbal medicine for centuries for various health problems. It has a beneficial effect of Reducing serum lipids and cardiovascular system disease .The purpose of present study was to evaluate the effects of garlic and atorvastatine on the dyslipidemic people. Aim: The aim of this study is to assist the affectivity of the garlic in lowering the lipid profile in hyperlipidemic patients as well as the affect of time on treatment.Methods: This 12 week, Garlic treated, atorvastatin, Garlic + atorvastatin and non treated study was conducted on patients with hyperlipidemia (n=40) were divided into 4 groups each comprising 10 patients, first group was control healthy persons, second group was given garlic capsules (500mg) twice daily, third group was given atorvastatin (40mg-Gulf pharmaceutical), fourth group was given both garlic capsules + atorvastatin. Results: After 12 week the garlic + atorvastatin treated group had good results in reduction of total cholesterol (5.23±0.12) triglycerides (1.93±0.12) LDL (1.31±0.14) VLDL (0.87±0.15) as compared with those before treatment. Conclusion: This study suggests that using garlic capsules + atorvastatin in treating dyslipidemia patients are efficiently reduced serum total cholesterol, LDL,VLDL and moderately raised HDL cholesterol as compared with non-treated group ,in addition prolong duration of treatment will assess the benefit effect of garlic + atorvastatin in treatment of dyslipidemia and other cardiovascular system diseases.

المقدمة: فرط شحميات الدم ( dyslipidemia ) واحد من الأمراض الأكثر شيوعا بين المجتع العراقي واستخدام الأدوية العشبية في علاج فرط شحميات الدم كان خيارا جيدا للحد من الآثار الجانبية للعقاقير الموصى بها مع أعطائه نتائج جيدة من الشفاء، الثوم (Allium sativum) استخدم في الطب التداوي بالاعشاب لقرون لعلاج مشاكل صحية مختلفة، وله تأثير مفيد في تخفيض نسبة الدهون في الدم وأمراض القلب والأوعية الدموية. طريقة العمل: استغرق العلاج 12أسبوع ، وقد أجري على النحو التالي :عدد العينات (ن = 40) وقسمت إلى 4 مجاميع كل مجموعة تضم 10 عينات، المجموعة الأولى هي مجموعة السيطرة وتمثل الأصحاء، المجموعة الثانية (مرضى يعانون من فرط شحميات الدم )أعطوا كبسول من الثوم (حجم 500mg) مرتين يوميا ، وأعطيت المجموعة الثالثة (مرضى يعانون من فرط شحميات الدم) أتورفاستاتين (40 mg)، وأعطيت المجموعة الرابعة (مرضى يعانون من فرط شحميات) كبسول من الثوم500mg + أتورفاستاتين 40mg. النتائج: بعد 12 أسبوع من اعطاء الثوم + أتورفاستاتين ظهرت نتائج جيدة في الحد من الكولسترول الكلي (5.23 ± 0.12)TCو الدهون الثلاثية (1.93 ± 0.12) LDL (1.31 ± 0.14) VLDL (0.87 ± 0.15)TG بالمقارنة مع تلك قبل العلاج. الخلاصة: تشير هذه الدراسة إلى أن استخدام كبسول الثوم + أتورفاستاتين في علاج مرضى فرط شحميات الدم يساعد في تخفيض الكولسترول الكلي في الدم و LDLو VLDL بالمقارنة مع المجموعة غير المعالجة، بالإضافة الى إطالة مدة العلاج باستعمال الثوم + أتورفاستاتين سيعطي نتائج افضل في علاج مرضى فرط شحميات الدم. الهدف: إن الهدف من هذه الدراسة هو تقييم كفاءة استعمال الثوم مع الادوية الاخرى في خفض الدهون لمرضى فرط شحميات الدم وكذلك تأثير عامل الوقت على العلاج.


Article
Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients
الاستجابة العلاجية لمستوى الدهون في مصل الدم عند مرضى السكري / النوع الثاني

Author: Riyadh M. Murtadha رياض مصطفى مرتضى
Journal: Iraqi Journal of Pharmaceutical Sciences المجلة العراقية للعلوم الصيدلانية ISSN: 16833597 Year: 2012 Volume: 21 Issue: 1 Pages: 21-26
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Lipid disorders and cardiovascular disease (CVD) risk are known to be increased in patients with diabetes mellitus. The effects of statins on serum lipid levels are well known; however, previous studies did not compare the effects of statins on serum lipid levels in diabetic patients with non-diabetic patients. To investigate the effects of Atorvastatin on serum lipid profiles in hyperlipidemic patients with type 2 diabetes mellitus in comparison with hyperlipidemic patients without diabetes.This study was conducted on 33 type 2 diabetic patients & 34 non-diabetic patients; their age range was 40-80 years, all of them were hyperlipidemic, who had been administered 10, 20, & 40 mg daily of Atorvastatin and completed a 6-month follow-up. Serum lipids were measured before and after treatment at 1, 3, and 6 months.It was found that the reduction in S. Total Cholesterol and S. LDL-C were less in diabetic patients than that in non-diabetic patients when they are using the same doses of Atorvastatin, while the changes in S. HDL-C and S. Triglyceride were nearly similar in both. Furthermore, it is noticed that nearly the same responses of S. Cholesterol and S. LDL-C reduction were achieved in diabetic patients when they are using doubled doses that are used for non-diabetic patients.So,higher doses of Atorvastatin (double doses) are needed to improve serum lipid levels in diabetic patients as compared to non-diabetic patients.

بما أن اضطرابات الدهون وخطر الأمراض القلبية الوعائية اكثر عند المرضى المصابين بداء السكري, وأنّ تأثيرات عقار الستاتين على مستويات الدهون في مصلِ الدم معروفة إلا ان الدراسات السابقة لَم تقارن تأثيرات عقار الستاتين على مستويات الدهون في مصلِ الدم عند المرضى المصابين بداء السكري مع غيرالمصابين, وبهدف تَحرّي تأثيرات عقار الاتورفاستاتين (Atorvastatin) على مستويات الدهون في مصلِ الدم عند المرضى المصابين بداء السكري بالمقارنة مع المرضى غير المصابين بالسكري الذين يعانون من زيادة الدهون بالدم ، اجريت هذه الدراسة على 33 مريض مصاب بداء السكري من النوع الثاني بالمقارنة مع 34 مريض غير مصاب بالسكري جميعهم لديهم زيادة مستوى الدهون بالدم ، تتراوح اعمارهم بين 40-80 سنة, قسموا الى مجاميع ليستخدموا عقار اتورفاستاتين 10, 20، و40 ملغ يومياً وليكملوا فترة متابعة مدة 6 شهور. تم قياس مستويات الدهون في مصلِ الدم قَبل وبعد المعالجة في الشهر الاول والثالث والسادس.اظهرت النتائج أن التغييرات في الكولستيرول الكلي والكولستيرول واطئ الكثافة في مصل الدم كانت أقل في المرضى المصابين بالسكري من تلك التي في المرضى غير المصابين بالسكري الذين استخدموا نفس الجُرَع من عقار الاتورفاستاتين (Atorvastatin)، بينما كانت التغييرات في الكولستيرول عالي الكثافة والدهون الثلاثية متماثل تقريباً في المجموعتين. علاوة على ذلك يُلاحظ بأنّ الاستجابة كانت نفسها تقريباً للكولوستيرول الكلي والكولستيرول واطئ الكثافة في المرضى المصابين بالسكري عندما يستخدمون جُرَع مُضاعفة كالتي استخدمت للمرضى غير المصابين بالسكري. نستنتج من ذلك أن المرضى المصابين بالسكري يحتاجون الى جُرَع أعلى (جُرَع مضاعفة) من عقار الاتورفاستاتين (Atorvastatin)، لتحسين الاستجابة العلاجية لمستويات الدهون في الدم بالمقارنة مع المرضى غير المصابين بالسكري.


Article
USING ATORVASTATIN AND L-CARNITINE IN PREVENTION OF PILOCARPINE-INDUCED SEIZURES: ANIMAL MODEL STUDY

Authors: Uday AR. Hussein عدي عبد الرضا حسين --- Faruk H. Al-Jawad فاروق حسن الجواد
Journal: IRAQI JOURNAL OF MEDICAL SCIENCES المجلة العراقية للعلوم الطبية ISSN: P16816579,E22244719 Year: 2014 Volume: 12 Issue: 2 Pages: 156-160
Publisher: Al-Nahrain University جامعة النهرين

Loading...
Loading...
Abstract

Background:Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures.Objective:To investigate the possible antiepileptic effect of both atorvastatin and L-carnitine on seizure induced by pilocarpine.Methods:Fifty male albino mice weighing between 30-35 gm were equally allocated into five groups (each group contained 10 mice) and were given one of the following; control group; distal water group (0.1 ml), diazepam group (1mg/kg), atorvastatin group (5 mg/kg) and L-carnitine group (300 mg/kg). All animals (except normal group) were injected with Pilocarpine hydrochloride (350 mg/kg) to induce generalized tonic-clonic seizures 30 minutes after the tested drugs had been administrated. The mean onset of seizure were determined as well as the mean serum concentration of electrolytes, glutathione (GSH) and malondialdehyde (MDA) were measured after seizure had been induced.Results:Pilocarpine induced seizure at approximately 7 minutes after injection, while both atorvastatin and L-carnitine produced highly significant increase in mean onset of seizure 14 ± 0.471 and 14.5 ± 0.909 respectively as compared to that of D.W. group, also both drugs produced highly significant changes in mean serum concentration of electrolytes, GSH and MDA.Conclusion:Atorvastatin and L-carnitine had antiepileptic effects against seizures induced by pilocarpine when used at applied doses.Key words:Epileptic seizure, Atorvastatin and L-carnitine.


Article
Antihyperlipidemic Effect of L-Thyroxine Combined with Carvedilol in Induced Hyperlipidemia in Rabbits

Authors: Muayyad Sraibit Abbod --- Faruk H. Al-Jawad --- Adnan A. Anoze --- Mufeda Ali Jawad
Journal: Medical Journal of Babylon مجلة بابل الطبية ISSN: 1812156X 23126760 Year: 2014 Volume: 11 Issue: 4 Pages: 1047-1059
Publisher: Babylon University جامعة بابل

Loading...
Loading...
Abstract

Background:Hyperlipidemia is defined as an elevation of one or more of the plasma lipids, including cholesterol, cholesterol esters, triglycerides (TG) and phospholipids .An elevation of plasma lipids may be caused by primary or secondary factors.Objective:To evaluate the effect of L-thyroxine - Carvedilol combination on hyperlipidemia induced in rabbits. Material and method:Forty healthy, domestic rabbits of both sexes, weighing (800 – 1100 grams) were used in this study. They were divided into five groups each one contains eight rabbits. The first group (G1) was given a standard diet to be considered as a control group while all other groups fed with high cholesterol diet. The second group (G2) was given high cholesterol diet only, third group (G3) treated with atorvastatin , (G4) treated with L-thyroxine and (G5) received L-thyroxine combined with carvedilol. Then lipid profile, heart rate and body weight were measured for all groups to be compared. Results:Because atorvastatin is a known antihyperlipidemic drug, the results of using combination of L-thyroxin with carvedilol were compared to those produced by atorvastatin alone. The results showed insignificant (p˂0.05) difference in all biochemical parameters, heart rate and body weight of the hyperlipidemic group treated with the combination of L- thyroxin and carvedilol (G5) when compared with those treated with atorvastatin alone (G3). Conclusion:The use of the combination of L-thyroxine and carvedilol has antihyperlipidemic effect similar to that of atorvastatin which is well known antihyperlipidemic drug.


Article
Hepatotoxicity of Combined Therapy of Atorvastatin with Platelet P2Y12-ADP Receptor Antagonist in Coronary Heart Disease Treated Patients

Authors: Feryal Hashim Rada --- Najat Abdulrazzaq Hasan --- Mohammed Hasan Al Baghdadi
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2015 Volume: 14 Issue: 1 Pages: 108-113
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT : BACKGROUND: Clopidogrel, an adenosine diphosphate receptor blocker, is widely used as an adjunctive antiplatelet therapy in coronary disease and percutaneous coronary stenting. It appears to be a safe drug with few occurrences of liver side-effects that usually resolved after drug withdrawal.OBJECTIVE: The goal of this study was to investigate whether the co-administration of atorvastatin could aggravate the hepatic - toxicity of clopidogrel.PATIENTS AND METHODS: Eighty patients with coronary disease were included in this study. All patients received a dose of 75 mg/day of clopidogrel. Forty patients group A with recent treatment (˂ 3 months) of clopidogrel; other forty patients group B with (˃ 1 year) treatment of clopidogrel. Liver function tests were measured and studied at baseline (clopidogrel without atorvastatin) and at 2, 4, 6 weeks of clopidogrel with atorvastatin (40 mg/day) afterwards.RESULTS: Liver function tests with co-therapy showed high significant elevation in mean serum total alkaline phosphatase (P˂0.001), significant decrease (P˂ 0.05) in mean serum gamma-glutamyl transferase ,significant elevation (P˂ 0.05) in mean serum direct bilirubin and insignificant elevation (P˃0.05) in mean serum total bilirubin , whereas the results appeared within normal range in mean serum levels of alanine aminotransferase, aspartate aminotransferase ,glutamate dehydrogenase -1,and total protein .CONCLUSION: Combination of atorvastatin and clopidogrel may induce hepatic injury cholestatic type resulting from abnormal bile flow caused by either drugs or its metabolites.KEYWORDS: clopidogrel; atorvastatin; liver function tests.


Article
Efficacy of simvastatin compared with atorvastatin in patients with hyperlipidaemia in Kurdistan
فعالية سيمفاستاتين مقارنة مع أتورفاستاتين في مرضى فرط شحميات الدم في كردستان

Authors: Ari Aziz Salih --- Wishyar Abbas Hamad --- Showan D. Husain
Journal: Zanco Journal of Medical Sciences مجلة زانكو للعلوم الطبية ISSN: 19955588/19955596 Year: 2012 Volume: 16 Issue: 2 Pages: 90-97
Publisher: Hawler Medical Univeristy جامعة هولير الطبية

Loading...
Loading...
Abstract

Background and objectives: Lowering the blood cholesterol and low density lipoprotein levels may reduce the risk of coronary heart disease. This study was designed to evaluate the effect of lipid-lowering therapy by simvastatin 20 mg versus atorvastatin 20mg on patients suffering from hyperlipidemia.Method: This study is 16-weeks duration included 75 patients with hyperlipidemia. Patients were assigned randomly to receive either simvastatin 20 mg/day group (1), or atorvastatin 20 mg/day group (2). After 12 hours fasting, lipid profile, atherogenic index and alanine aminotransferase were assessed for the patients at baseline, 8-weeks and at the end of 16-weeks of treatment.Results: After therapy for both groups of patients, as compared to the levels at the baseline, the serum total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) were significantly reduced while high density lipoprotein cholesterol (HDL-C) was significantly increased. Serum alanine aminotransferase (ALT) increased by both groups of treatment with no significant differences between the two modes of treatment.Conclusion: After treatment with simvastatin 20 mg and atorvastatin 20 mg, there were a reduction in total cholesterol, triglyceride, LDL-C, and VLDL-C, and an increase in HDL-C in both groups. Comparing the two types of treatment, atorvastatin 20 mg was more effective in lowering triglyceride and VLDL-C than simvastatin 20 mg while Simvastatin led to greater reduction in LDL-C. Both modes of treatment were well tolerated by the patients.


Article
Effect of atorvastatin, with or without ezetimibe, on serum lipid profile and ALT in hyperlipidemic patients
تأثير أتورفاستاتين ، مع أو بدون ezetimibe ، على الملف الدهني للدهون و ALT في مرضى شحميات الدم

Authors: Wishyar Abbas Hamad --- Showan D. Husain
Journal: Zanco Journal of Medical Sciences مجلة زانكو للعلوم الطبية ISSN: 19955588/19955596 Year: 2011 Volume: 15 Issue: 1 Pages: 13-19
Publisher: Hawler Medical Univeristy جامعة هولير الطبية

Loading...
Loading...
Abstract

Background and objectives: Hyperlipidaemia is raised serum levels of one or more of total cholesterol, low-density lipoprotein and triglycerides. Many drugs have been used for the treatment of this disorder. This work compares the effects of atorvastatin with or without ezetimibe on lipid profile, atherogenic index and serum alanine aminotransferase.Methods: This study covers 90 subjects, 60 untreated hyperlipidemic patients, and 30 healthy subjects. Patients were divided into 2 groups, the first group included 30 patients treated with atorvastatin 20 mg/day alone, the second group included 30 patients treated with a combination of 2 drugs (atorvastatin 10 mg plus ezetimibe 10 mg) taken daily at night. Serum lipid profile, atherogenic index and serum alanine amniotransferase were measured after 12 hours fasting for the patients in 3 intervals: before, and after 8 weeks and 16 weeks of treatment.Results: After therapy for both groups of patients, as compared to the levels before treatment, has shown that serum total cholesterol, triglycerides, low density lipoprotein cholesterol and very low density lipoprotein cholesterol were significantly reduced while high density lipoprotein cholesterol was significantly increased. Serum alanine aminotransferase increased by both groups of treatment with no significant difference between the two modes of treatment which has the same findings in comparison to the control group.Conclusion: Combination of atorvastatin 10 mg and ezetimibe 10 mg daily, is more effective than atorvastatin 20 mg taken alone.


Article
Study The Effects of Extracted Octacosanol and Atorvastatin on Leukocytes in Female Norwegian Rats.

Author: Ashwaq Jabbar Al-Miahy
Journal: Journal of Education for Pure Science مجلة التربية للعلوم الصرفة ISSN: 20736592 Year: 2019 Volume: 9 Issue: 2 Pages: 211-216
Publisher: Thi-Qar University جامعة ذي قار

Loading...
Loading...
Abstract

Abstract:The present study was designed to compare some of hematological parameters in female norwegianrats (Ratus norvigicus) after administration of extracted octacosanol and atorvastatin. Thirty-two femalesrat with (10-12) weeks old-and weighting (200-250 gm) were used in the current study. Policosanol wasextracted from sugarcane that obtained from Mesan province. Octacosanol is determined in this extractionby gas chromatography – mass spectrometry (GC/MS). Animals were divided into 4 equal groups: Group.1(n=8) (Control): only 0.٥ ml/ kg of Dimethyl Sulphoxide (DMSO). Group.2 (n=8) animals treated with(0.02 mg/ kg) of standard octacosanol. Group.3 (n=8) animals treated with (0.02mg/ kg) of octacocosanolextraction, Group. 4 (n=8) treated with only (0.02mg/ kg) of atorvastatine. The treatment continued for 30days. All animals were then sacrificed and blood samples were collected in EDTA tubes for measuring oftotal and different count of WBC.


Article
Effect of Atorvastatin on Bone biochemical markers in dyslipidemic patients, Basra, Iraq
تأثير عقار الا تورفاستاتين على المؤشرات الحيوية للعظام في المرضى الذين يعانون من داء الشحام،في البصرة-العراق

Author: Falah H. Shari فلاح شاري
Journal: nursing national Iraqi specility المجلة العراقية الوطنية للعلوم التمريضية ISSN: 18122388 Year: 2016 Volume: 29 Issue: 1 Pages: 51-62
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Objective: The aim of the study was to estimate the action atorvastatin(20mg/day) on bone biochemical markers dyslipidemic men.Methodology: This study was conducted between May 2015 and November 2015 in Al-Basrah General hospital in Basra, Iraq, to evaluate important role of atorvastatin (20mg/day)(Lipitor® Pfizer Pharma GmbH.Germany) on bone biochemical markers. Thirty men patients who had been admitted for a variety of medical problems included in the study. All the patients had previously been diagnosed with Dyslipidemia by specialist physician in internal medicine and all patients age below 55 years . the inclusion criteria for the experimental group was use of atorvastatin for at least three months; the study group was then compared to age-matched healthy men .bone biochemical markers were compared between groups. Results are expressed mean ± SD; statistically Student’s t test was used to compare variables.Results: The mean age of the statin group was 44.5 ± 5.9 and control group was 45.7 ± 4.4.After 3 months treatment with atorvastatin, as in table (1) and figures (1-8) Surprisely level of serum total cholesterol remain significantly higher than value of normal healthy group. LDL value significantly reduced by treatment but still significantly higher than values of normal group. HDL value were significantly higher than that of its initial values, but level of HDL ;after treatment; was not significantly different from that of normal group. Triglycerides was not significantly changed by treatment and its value still significantly higher than normal group. Vit D level was not significantly change by treatment and its value was significantly lower than normal group. Osteocalcin was elevated significantly by treatment; and this elevation was significantly as compared with its initial value and with that of normal group. Amino Terminal telopeptide procollagen type I (NTX-I) was not significantly change by treatment and its value still significantly higher than normal group and before treatment values. Also body mass index value was not significantly changed by treatment. Recommendations: Further studies are recommended to confirm the positive effects of atorvastatin and other statins on bone biochemical markers with larger number of patients and longer period of follow up. Also other bone formation and resorption markers are recommended to determine the expected mechanisms of action of statins on bone remodeling processes.

الهدف : وكان الهدف من الدراسة لتقييم عمل الأتورفاستاتين (20 ملغ / يوم) على المؤشرات الحيوية لعظام الرجال المصابين بداء الشحام. المنهجية: وقد أجريت هذه الدراسة بين ايار 2015 وتشرين الاول من 2015 في مستشفى البصرة العام في البصرة، العراق، لتقييم الدور الهام للاتورفاستاتين 20ملغم من شركة فايزر الدوائية(لبتور,المانيا) على المؤشرات الحيوية للعظام. وقد شارك بالدراسة ثلاثين رجل من الذين ادخلوا للمستشفى نتيجة المشاكل الطبية المتنوعه. وقد تم تشخيص جميع المرضى المصابين بالشحام مسبقا من قبل الطبيب المختص في الطب الباطني. وجميع المرضى تقل أعمارهم عن 55 سنة من العمر. وكانت معايير الشمولية للمجموعة التجريبية للمرضى الذين استخدموا الأتورفاستاتين لمدة ثلاثة أشهر على الأقل. ثم قارن فريق الدراسة إلى تطابق سن الرجال الأصحاء . تمت مقارنة بين المؤشرات الحيوية بين المجاميع. تم التعبير احصائيا باستخدام المعدل ± الانحراف المعياري تم استخدام اختبار t للمقارنة بين المتغيرات. النتائج: وكان متوسط العمر لمجموعة الستاتين هو 44.5 ± 5.9 ومجموعة الاصحاء او السيطرة هو 45.7 ± 4.4 بعد ثلاثة اشهر من علاج الأتورفاستاتين، كما في الجدول (1) والاشكال من (1-8) تبين بصورة مفاجئة ان مستوى مجموع الكولسترول في الدم أعلى بكثير من مستوى مجموعة الاصحاء او السيطرة. كما تبين ان مستوى الدهون قليلة الكثافة انخفض انخفاضا كبيرا باستخدام العلاج ولكن لا يزال أعلى بكثير من قيم مجموعة الاصحاء. كما ان قيمة الدهون عالية الكثافه أعلى بكثير من القيم الأولية. ولكن مستوى هذه الدهون ، وبعد العلاج؛ كان لا تختلف كثيرا عن مجموعة الاصحاء الطبيعية. اما الدهون الثلاثية. لم تتغير بشكل كبير عن طريق العلاج وقيمته لا يزال أعلى من مجموعة الاصحاء. لم يتغير مستوى فيتامين دي بشكل كبير عن طريق العلاج وكان قيمتها قلت بشكل ملحوظ من مجموعة الاصحاء. بينما ارتفع مستوى الاوستيوكالسين بشكل ملحوظ عن طريق العلاج. وكان هذا الارتفاع بشكل ملحوظ بالمقارنة مع القيمة الأولية ومع أن مجموعة الاصحاء الطبيعية. مستوى التايلوبيبتيدات ذات الامينات الطرفية لم تتغير بشكل كبير عن طريق العلاج وقيمتها لا تزال اعلى من مجموعة الاصحاء والقيم الاولية (قبل بدء العلاج).التوصيات: اوصت هذه الدراسة بوجود الآثار الإيجابية للأتورفاستاتين (20 ملغ / يوم) على المؤشرات الحيوية للعظام على الاقل بعد ثلاثة أشهر من العلاج.وكذلك اوصت باستخدام عقار الاتورفستاتين لتقليل خطر الكسور بالنسبة لمرضى داء الشحام.


Article
Effect of Very Early Atorvastatin Initiation for Acute Myocardial Infarction on Creatine Kinase release

Authors: Adnan A. Al.adeem عدنان العديم --- Lewai S. Abdulaziz لؤي عبد العزيز --- Faris Abdul Kareem فارس عبد الكريم
Journal: Al-Kindy College Medical Journal مجلة كلية الطب الكندي ISSN: 18109543 Year: 2010 Volume: 6 Issue: 1 Pages: 79-84
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background : It has been suggested that pre-treatment with a statin agent prior to myocardial infarction limits myocardial creatine kinase release, and thus may act to limit myocardial infarct size in humans.Objective : To examine the effect of very early statin initiation for acute myocardial infarction (AMI), to the extent of myonecrosis as manifested by peak serum creatine kinase levels.Methods : Patients with AMI admitted to Al-Kindy teaching hospital cardiac care unit from 1st February 2007 to 28th February 2008, who fulfilled the inclusion criteria cited in the present study, were randomly assigned into two study groups. The statin group patients have received a single oral dose of 40 mg atorvastatin at time of admission and repeated for the next days until discharge, patients not receiving statin were considered as controls, blood samples were obtained on admission and every 8 h for another three consecutive samples to identify peak creatine kinase levels.Results : Patients who had statin therapy initiated immediately after hospital admission have similar peak creatine kinase concentrations as compared to those not receiving statin therapy ( P= 0.332).Conclusion : statin initiation in AMI patients fails to show any observable effect on creatine kinase release, the need of an extended period for the statin agent to achieve the predictable outcome may suggest the necessity of statin pretreatment in patients at high risk for AMI.

Listing 1 - 10 of 23 << page
of 3
>>
Sort by
Narrow your search

Resource type

article (23)


Language

English (21)

Arabic (1)

Arabic and English (1)


Year
From To Submit

2019 (3)

2018 (1)

2017 (1)

2016 (2)

2015 (4)

More...